Ubs Group Ag Atreca, Inc. Transaction History

Ubs Group Ag

  • $400 Billion
  • Q2 2024

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 09, 2024
BUY
$0.13 - $0.38 $751 - $2,196
5,779 Added 89.86%
12,210 $1,000
Q3 2023

Nov 09, 2023
SELL
$0.26 - $1.12 $520 - $2,242
-2,002 Reduced 23.74%
6,431 $1,000
Q2 2023

Aug 11, 2023
BUY
$0.88 - $1.22 $1,761 - $2,442
2,002 Added 31.13%
8,433 $8,000
Q1 2023

May 12, 2023
BUY
$0.91 - $1.82 $1,818 - $3,636
1,998 Added 45.07%
6,431 $7,000
Q4 2022

Feb 08, 2023
BUY
$0.78 - $1.68 $3,410 - $7,346
4,373 Added 7288.33%
4,433 $3,000
Q3 2022

Nov 10, 2022
SELL
$1.59 - $2.74 $7,188 - $12,387
-4,521 Reduced 98.69%
60 $0
Q2 2022

Aug 10, 2022
SELL
$1.56 - $3.25 $4,431 - $9,233
-2,841 Reduced 38.28%
4,581 $8,000
Q1 2022

May 16, 2022
SELL
$1.61 - $5.2 $3,672 - $11,861
-2,281 Reduced 23.51%
7,422 $23,000
Q4 2021

Feb 14, 2022
BUY
$2.87 - $6.29 $17,053 - $37,375
5,942 Added 157.99%
9,703 $29,000
Q3 2021

Nov 15, 2021
SELL
$4.91 - $9.07 $29,302 - $54,129
-5,968 Reduced 61.34%
3,761 $23,000
Q2 2021

Aug 13, 2021
SELL
$7.82 - $13.8 $170,624 - $301,102
-21,819 Reduced 69.16%
9,729 $83,000
Q1 2021

May 12, 2021
BUY
$13.0 - $19.34 $393,848 - $585,924
30,296 Added 2419.81%
31,548 $484,000
Q4 2020

Feb 11, 2021
BUY
$13.03 - $17.09 $8,195 - $10,749
629 Added 100.96%
1,252 $20,000
Q3 2020

Nov 12, 2020
SELL
$12.67 - $23.19 $84,825 - $155,257
-6,695 Reduced 91.49%
623 $9,000
Q2 2020

Jul 31, 2020
SELL
$12.52 - $23.45 $21,546 - $40,357
-1,721 Reduced 19.04%
7,318 $156,000
Q1 2020

May 01, 2020
SELL
$11.4 - $27.28 $6,999 - $16,749
-614 Reduced 6.36%
9,039 $150,000
Q4 2019

Feb 14, 2020
BUY
$9.68 - $18.67 $35,738 - $68,929
3,692 Added 61.94%
9,653 $149,000
Q3 2019

Nov 14, 2019
BUY
$10.42 - $22.04 $46,629 - $98,629
4,475 Added 301.14%
5,961 $73,000
Q2 2019

Aug 14, 2019
BUY
$17.07 - $18.84 $25,366 - $27,996
1,486 New
1,486 $28,000

Others Institutions Holding BCEL

# of Institutions
2
Shares Held
30.6K
Call Options Held
0
Put Options Held
0
View Full List

About Atreca, Inc.

BCEL Quotes by TradingView
  • Ticker BCEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,876,000
  • Description
  • Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...
More about BCEL
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email